gefitinibhttp://www.unboundmedicine.com/medline/ebm/research/gefitinibUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.http://www.unboundmedicine.com/medline/ebm/record/19922469/full_citation/Epidermal_growth_factor_receptor_in_relation_to_tumor_development:_EGFR_gene_and_cancer_Mitsudomi T, Yatabe Y 
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. [JOURNAL ARTICLE]
FEBS J 2009 Nov 18.
Abstract | Full Citation | Find Related Articles Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.http://www.unboundmedicine.com/medline/ebm/record/19922468/full_citation/Epidermal_growth_factor_receptor_in_relation_to_tumor_development:_EGFR_targeted_anticancer_therapy_Okamoto I 
Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. [JOURNAL ARTICLE]
FEBS J 2009 Nov 18.
Abstract | Full Citation | Publisher Full Text | Find Related Articles EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.http://www.unboundmedicine.com/medline/ebm/record/19922467/full_citation/EGF_receptor_in_relation_to_tumor_development:_molecular_basis_of_responsiveness_of_cancer_cells_to_EGFR_targeting_tyrosine_kinase_inhibitors_Takeuchi K, Ito F 
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. [JOURNAL ARTICLE]
FEBS J 2009 Nov 18.
Abstract | Full Citation | Find Related Articles Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.http://www.unboundmedicine.com/medline/ebm/record/19921194/full_citation/Combined_inhibition_of_IGFR_enhances_the_effects_of_gefitinib_in_H1650:_a_lung_cancer_cell_line_with_EGFR_mutation_and_primary_resistance_to_EGFR_TK_inhibitors_Choi YJ, Rho JK, Jeon BS, et al. 
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. [JOURNAL ARTICLE]
Cancer Chemother Pharmacol 2009 Nov 18.
Abstract | Full Citation[A Case of Adenocarcinoma of the Lung with a Long-Term Therapeutic Effect Due to S-1 Administered as the Sixth Regimen.]http://www.unboundmedicine.com/medline/ebm/record/19920394/full_citation/[A_Case_of_Adenocarcinoma_of_the_Lung_with_a_Long_Term_Therapeutic_Effect_Due_to_S_1_Administered_as_the_Sixth_Regimen_]Okudera K, Takanashi S, Hayashi A, et al. 
[A Case of Adenocarcinoma of the Lung with a Long-Term Therapeutic Effect Due to S-1 Administered as the Sixth Regimen.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1889-1891.
Abstract | Full Citation | Find Related Articles American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.http://www.unboundmedicine.com/medline/ebm/record/19917871/full_citation/American_Society_of_Clinical_Oncology_Clinical_Practice_Guideline_Update_on_Chemotherapy_for_Stage_IV_Non_Small_Cell_Lung_Cancer_Azzoli CG, Baker S, Temin S, et al. 
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. [JOURNAL ARTICLE]
J Clin Oncol 2009 Nov 16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles MicroRNA Expression Profiles in Lung Cancer Cooperated with Drug Sensitivity to EGFR Tyrosine Kinase Inhibitor.http://www.unboundmedicine.com/medline/ebm/record/19915314/full_citation/MicroRNA_Expression_Profiles_in_Lung_Cancer_Cooperated_with_Drug_Sensitivity_to_EGFR_Tyrosine_Kinase_Inhibitor_Seike M 
MicroRNA Expression Profiles in Lung Cancer Cooperated with Drug Sensitivity to EGFR Tyrosine Kinase Inhibitor. [Journal Article]
J Nippon Med Sch 2009 Oct; 76(5):275-6.
Abstract | Full CitationGefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.http://www.unboundmedicine.com/medline/ebm/record/19898796/full_citation/Gefitinib_induces_apoptosis_and_decreases_telomerase_activity_in_MDA_MB_231_human_breast_cancer_cells_Moon DO, Kim MO, Heo MS, et al. 
Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. [Journal Article]
Arch Pharm Res 2009 Oct; 32(10):1351-60.
Abstract | Full CitationThis month in APR.http://www.unboundmedicine.com/medline/ebm/record/19898793/full_citation/This_month_in_APR_Lee CH 
This month in APR. [Journal Article]
Arch Pharm Res 2009 Oct; 32(10):1333-4.
Full Citation | Publisher Full Text | Find Related Articles A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705.http://www.unboundmedicine.com/medline/ebm/record/19898258/full_citation/A_Phase_II_Trial_of_Erlotinib_Monotherapy_in_Pretreated_Patients_with_Advanced_Non_small_Cell_Lung_Cancer_Who_Do_Not_Possess_Active_EGFR_Mutations:_Okayama_Lung_Cancer_Study_Group_Trial_0705_Yoshioka H, Hotta K, Kiura K, et al. 
A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705. [JOURNAL ARTICLE]
J Thorac Oncol 2009 Nov 5.
Abstract | Full Citation